Pharmaceutical company Amanta Healthcare Ltd. is launching its Initial Public Offering (IPO) today, September 1, 2025. The bidding window for the Amanta Healthcare IPO will be open till September 3, 2025, for public subscription. The company is known for specialising in creating, producing, and selling sterile liquid formulations and medical devices.
The bidding window for the Amanta Healthcare IPO will be open till September 3, 2025, for public subscription. The allotment process is expected to be finalised on September 4, 2025, and the company’s shares will be listed on both BSE and NSE. The tentative listing date is fixed as September 9, 2025.
Amanta Healthcare will be a bookbuilding consisting entirely of a fresh issue of 1 crore equity shares. The issue price band is set at ₹120 to ₹126 per share. The minimum lot size for an application is 119, and the minimum investment amount required for a retail investor is ₹14,994 (119 shares).
Beeline Capital Advisors Pvt.Ltd is the book-running lead manager, and MUFG Intime India Pvt.Ltd is the registrar for the Amanta Healthcare IPO.
(September 1, 2025, 05:00 PM)
On Day 1, Amanta Healthcare IPO saw a subscription of 4.61 times as per the NSE data. The public issue was subscribed 6.70 times in the retail category, 0.04 times in the QIB category, and 5.81 times in the NII category.
The Company will utilise the net proceeds from the issue for the following purposes:
Explore other Upcoming IPOs on BSE and NSE.
Amanta Healthcare Ltd., founded in 1994 in Ahmedabad, is a pharmaceutical company that manufactures sterile liquid medicines, including injections, eye drops, respiratory solutions, and irrigation fluids. It utilises advanced technologies, such as Blow-Fill-Seal (BFS), to ensure high quality.
The company has a wide portfolio of over 45 generic medicines, supplied in India and abroad. Its large manufacturing facility in Gujarat is WHO-GMP certified and equipped with modern production lines for both large and small-volume injectables. In FY25, Amanta recorded a revenue of ₹276 crore with a net profit of ₹10.5 crore.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.